« Previous
Next »
Titles
- M10: bioanalytical method validation and study sample analysis : guidance for industry1
- M7(R2) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk: guidance for industry1
- Managed care1
- Mandated benefits1
- Manufacturers may need additional guidance to ensure consistent calculations of average sales prices1
- Many Medicaid enrollees with opioid use disorder were treated with medication: however, disparities present concerns1
- Maternal health: Availability of hospital-based obstetric care in rural areas : report to congressional committees1
- Maternal health: Outcomes worsened and disparities persisted during the pandemic : report to congressional addressees1
- Medicaid Fraud Control Units fiscal year 2022 annual report1
- Medicaid Managed Care: Rapid spending growth in state directed payments needs enhanced oversight and transparency : report to congressional addressees1
- Medicaid program integrity: Opportunities exist for CMS to strengthen use of state auditor findings and collaboration : report to congressional requesters1
- Medicaid: CMS oversight and guidance could improve Recovery Audit Contractor program : report to congressional requesters1
- Medicaid: CMS should assess effect of increased telehealth use on beneficiaries’ quality of care : report to congressional committees1
- Medicaid: Characteristics of and expenditures for adults with intellectual or developmental disabilities : report to congressional requesters1
- Medicaid: Efforts to address fraud in nonemergency medical transportation : report to congressional committees1
- Medical errors and patient safety1
- Medicare Advantage: Continued monitoring and implementing GAO recommendations could improve oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Medicare Advantage: Plans generally offered some supplemental benefits, but CMS has limited data on utilization : report to congressional committees1
- Medicare Part B drug payments: impact of price substitutions based on 2020 average sales prices1
- Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices1